Buzzy AI health startup Superpower is making another acquisition to power its food-as-medicine push
Superpower is building a health AI "super app" that combines biannual lab tests with users' health histories to create personalized lifestyle recommendations. The startup announced $30 million in Series A funding, led by Forerunner, just last month.
Now, Superpower is buying at-home lab testing company Base, Business Insider has learned exclusively.
Base, started by former Amazon engineer Lola Priego, provides at-home blood and saliva tests to help consumers improve habits like their sleep and diet with personalized lifestyle recommendations.
It was Base's diet analysis business that sold Superpower on the deal. Superpower CEO Jacob Peters told BI that the startup bought Base primarily for its wealth of nutritional data, which he said "would save us a lot of clinical R&D" as Superpower digs deeper into food-as-medicine care.
Terms of the deal were not disclosed. Priego launched Base in 2019, and the company last raised a $3.4 million seed round in 2021 led by Female Founders Fund.
Superpower is far from the only player interested in the nutrition market. Investors are pouring hundreds of millions of dollars into nutrition care startups like Nourish and Fay Nutrition, while movements like Robert F. Kennedy Jr.'s " Make America Healthy Again" are taking hold.
Those trends, too, are picking up steam with the explosion of weight-loss drugs like Ozempic and a growing consumer fascination with longevity, as some look to hack their health and extend their lifespans.
Superpower hits on that longevity care demand, with scores provided on its app measuring users' "biological age" and overall health. The startup even hired its own "chief longevity officer" in September.
Still, Peters said Superpower isn't a longevity startup, adding that he thinks most consumers simply want to get a better hold on their health — "If you superpower your health, you superpower your life."
Superpower is making M&A central to its strategy, an unusual approach for an early-stage startup. Base is its second acquisition of the year; Superpower bought women's health startup Feminade in January.
Peters said he expects to see more consolidation across digital health to combine point solutions tackling small slices of the market. And Superpower itself wants to connect a broad range of offerings into its app so patients can get all of their health needs met in one place.
"This probably won't be our last M&A," Peters laughed.
Reimagining concierge care with AI
Peters launched Superpower in 2023 alongside cofounders Max Marchione and Kevin Unkrich, CTO, born from their personal experiences with a broken healthcare system. Peters, for one, was diagnosed with the autoimmune disorder Crohn's disease a few years ago and spent four months in the hospital, undergoing multiple surgeries and racking up seven-figure bills.
"It was a big light bulb moment for me: as a person with health challenges, no one's really coming to save you," he said.
He and the Superpower team set out to create an AI-powered experience inspired by concierge medicine, which typically offers more attentive healthcare at a higher price tag, and making that style of care more widely accessible with technology. Its approach has attracted investors from Susa Ventures to Cameron and Tyler Winklevoss.
Superpower's members take biannual lab tests, either at home or at one of Superpower's partner labs, to assess more than 100 blood biomarkers. The Superpower app then pulls in user data from patient medical records, the lab tests, and wearables, and surfaces AI-driven insights based on that data to help its members optimize their health across their nutrition, sleep, and hormones.
Superpower's AI-generated action plans are reviewed by human care teams behind the scenes. Users can message their care teams to get further combined guidance from those human providers and AI.
Many consumer health startups launch to focus on one or a few problems, as Ro and Hims and Hers did with conditions like erectile dysfunction and hair loss. Superpower wants to take a different approach, aiming to be comprehensive from day one, so the startup can be known for its platform rather than for any single offering, Peters said.
That ambition comes with a cost: Superpower's memberships run $500 a year. While lower than what most Americans spend on healthcare in a year, that price point could put the app out of reach for many consumers.
Peters said the Superpower team is thinking hard about how to make its services available to the largest group possible. Superpower launched to sell directly to consumers, but in the future, Peters said the startup may consider contracting with employers to cover the costs of its memberships for employees.
"We want to build a platform that makes it easy to get the world's best healthcare to everyone at very low and accessible costs. That's the north star for us, to put a healthcare super app and AI doctor on everyone's phone," he said.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Why Hims & Hers Health Stock Just Dropped
Key Points Hims & Hers Health stock missed on earnings last night. The company grew sales 73% and profits tripled, but Wall Street wanted more. Hims & Hers also reported negative free cash flow for the first half of the year. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS), the telehealth company famous for selling Ozempic lookalikes over the internet, is tumbling today, down 6.7% through 10:55 a.m. ET after missing in its second-quarter earnings report last night, on both the top and bottom lines. Heading into the report, analysts forecast Hims & Hers would earn $0.23 per share on $552 million in sales -- but Hims & Hers earned only $0.17 per share, and sales were less than $545 million. Hims & Hers' Q2 earnings But was the news really as bad as it seems? After all, while Hims & Hers "missed" on sales, it did still grow sales 73% year over year. That was twice as fast as it grew subscribers, too (31%), indicating that not only are more customers signing up for the company's services, but they're buying more, too. And while Hims & Hers missed on earnings, too, those earnings per share nearly tripled year over year. Really, the only "bad" number I see in the report concerns free cash flow (FCF). Through the first half of this year, Hims & Hers grew its operating cash flow only 13%, to $90 million (within a couple of percentage points of reported net income). However, the company spent massively on capital expenditures -- more than $100 million -- resulting in negative FCF for the first half of 2025. Investors seem unsure what to make of the news. At one point this morning, the stock had recovered all its losses, and even turned green, before falling back into the red. Is Hims & Hers stock a sell? So how should investors react to this conflicting news? At $13.6 billion in market capitalization, Hims & Hers stock costs a pricey 70 times trailing earnings. It's even more expensive when valued on FCF -- about 103 times. These might be acceptable valuations if earnings were to continue tripling year after year. In fact, though, analysts see profits growing only 13% this year, and perhaps 57% next. For the time being, Hims & Hers stock remains too expensive to buy. Should you buy stock in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,103,313!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy. Why Hims & Hers Health Stock Just Dropped was originally published by The Motley Fool
Yahoo
22 minutes ago
- Yahoo
Experts reveal potential unintended side effect of Ozempic – and whether we should worry
The use of weight-loss jabs in the UK has skyrocketed, with an estimated 1.5 million people using them. Yet drugs like Ozempic and Wegovy don't just help people lose fat, but potentially muscle too, new research has suggested. A study that tested weight loss jabs on mice found that although muscle mass changes less than expected, muscles still get weaker and tissues like the liver also shrink. Weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. The medications, known as semaglutides, predominantly treat diabetes but are also available on the NHS or via private providers to help adults with a high body mass index (BMI). For example, although Ozempic is used for type 2 diabetes, it is sometimes prescribed off-label as a weight-loss drug. The results of the study, published in the journal Cell Metabolism, revealed Ozempic-induced weight loss decreased muscle mass by about 10 per cent. Most of this lost weight wasn't from skeletal muscles, which surround bones and joints, but instead from other tissues like the liver, which shrank by nearly half. However, because the Ozempic was tested on mice, researchers emphasise that more research is needed to determine whether similar changes to organ size occur in humans and whether those changes come with any risks. 'Loss of mass in metabolically active organs, such as the liver, is expected as part of healthy weight loss,' said Dr Ran Hee Choi, research instructor in nutrition and integrative physiology at the University of Utah college of health, and co-first author on the study. In both mice and humans, weight gain and loss can affect the size of organs like the liver without affecting their function. 'It's unlikely that the observed lean mass loss represents a serious adverse effect,' added Dr Takuya Karasawa, another co-first author on the study. Researchers found some skeletal muscles did shrink by about 6 per cent as the mice lost weight, but not enough to explain the overall muscle loss. However, when someone gains fat, they also tend to gain skeletal muscle. Study authors explain this is because the body needs to work harder to move around. As a result, losing extra fat can lead to a loss of muscle, which will not affect the person's overall quality of life. Researchers also tested the amount of force the mice's muscles exerted and found that some muscle strength decreased as the mice lost weight, even when the size of the muscle stayed roughly the same. This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility. 'The loss of physical function is a strong predictor of not just quality of life but longevity,' added Dr Katsu Funai, professor of nutrition at the University of Utah and the senior author on the study. Dr Funai concluded that further clinical trials of weight loss jabs should check for changes in muscle strength. A spokesperson for Novo Nordisk, which makes Ozempic, said: 'In clinical trial for Wegovy or Ozempic we did not specifically study the medicine's impact on muscle mass. In a sub-study of 140 patients with a BMI of 40 or less, analysis suggested that treatment with Wegovy was accompanied by reductions in both fat and lean body mass, with a greater reduction in fat mass than lean body mass. 'We recommend that any patients experiencing side effects while taking Wegovy or Ozempic contact their healthcare provider.'


Fox News
an hour ago
- Fox News
Raw milk from Florida farm sickens 21 people, including 6 children, health officials say
An outbreak of E. coli and Campylobacter tied to raw milk from a Florida farm has sickened 21 people, including six children, state health officials said. The Florida Department of Health issued a bulletin on Monday warning about the risks of drinking raw milk after 21 people, among them six kids under the age of 10, fell ill. Seven of the cases involved hospitalizations. "Severe complications" have been reported for at least two individuals, Florida health officials said. The illnesses are "linked to consumption of raw milk from the same farm," according to the bulletin. Raw milk is dairy milk that has not been pasteurized, a process that removes disease-causing germs by heating milk to a high enough temperature for a certain length of time, according to the U.S. Centers for Disease Control and Prevention (CDC). "In Florida, raw milk can only be sold for non-human consumption as pet or animal food, which limits regulation efforts of sanitary practices," the Florida Department of Health said. "Containers must have a label clearly stating that the raw milk is for animal consumption only." "Sanitation practices in this farm are of particular concern due to the number of cases." Because of the recent cases, the Florida Department of Health said it issued the bulletin "to assist Floridians in making informed decisions about their health." "Sanitation practices in this farm are of particular concern due to the number of cases," the bulletin said. Raw milk has seen a surge in popularity amid the Make America Healthy Again movement. But it's a drink that remains unregulated at the federal level, with individual states left to decide whether it's deemed safe for human consumption. "Many people consume raw milk safely," the Florida Department of Health said. However, raw milk can contain disease-causing bacteria that can lead to diarrhea, vomiting and stomach cramps, according to the CDC. "Choosing pasteurized milk is the best way to safely enjoy the nutritional benefits of milk," the CDC states on its website. Florida health officials haven't revealed the name of the farm linked to the outbreak.